Top Tweets for #OISASRS

Ophthalmology Times @OphthTimes

about 7 years ago

Up next: public company showcase with EyePoint, Aerie, Adverum, Oxurion, ReGenXBio #OISASRS @ModernRetina

0

1

0

0

0

Foundation Fighting Blindness

@FightBlindness

about 7 years ago

Dr. Patricia Zilliox, CEO of eyevensys and formerly CDO of FFB, presents novel protein production and delivery system for RP and other eye/retinal conditions. #oisasrs #eyevensys

FightBlindness's tweet photo. Dr. Patricia Zilliox, CEO of eyevensys and formerly CDO of FFB, presents novel protein production and delivery system for RP and other eye/retinal conditions. #oisasrs #eyevensys https://t.co/t3cXoOYoHG

0

4

2

0

0

Ophthalmology Times @OphthTimes

about 7 years ago

Patricia Zilliox highlights Eyevensys' EYS-611 for retinitis pigmentosis and dry AMD, plus 2 devices in development #OISASRS @ModernRetina

0

2

2

0

0

Ophthalmology Innovation Source @OISTWEETS

about 7 years ago

ReCLAIM-2B trial of Elamipretide in AMD targets full enrollment early 2020 with readout due 2021, Stealth Biotherapeutics Reenie McCarthiy CEO reports at #OISASRS

OISTWEETS's tweet photo. ReCLAIM-2B trial of Elamipretide in AMD targets full enrollment early 2020 with readout due 2021, Stealth Biotherapeutics Reenie McCarthiy CEO reports at #OISASRS https://t.co/nyGIsa5w1k

0

2

0

0

0

Ophthalmology Times @OphthTimes

about 7 years ago

Eyedaptic technology starting final beta push for market launch later this year, also highlighted case study of usage data, frequency, duration #OISASRS @ModernRetina

0

4

2

0

0

Foundation Fighting Blindness

@FightBlindness

about 7 years ago

Irene Wang of Belite presents oral molecule for inhibiting RBP4 —targeting Stargardt disease (phase 1) and dry AMD. #oisasrs

FightBlindness's tweet photo. Irene Wang of Belite presents oral molecule for inhibiting RBP4 —targeting Stargardt disease (phase 1) and dry AMD. #oisasrs https://t.co/UExijobyAl

0

5

3

0

0

Foundation Fighting Blindness

@FightBlindness

about 7 years ago

Dr. Susan Schneider of FFB partner Eloxx presents overview of company’s read-through molecules — some targeting inherited retinal diseases. #oisasrs

FightBlindness's tweet photo. Dr. Susan Schneider of FFB partner Eloxx presents overview of company’s read-through molecules — some targeting inherited retinal diseases. #oisasrs https://t.co/kDVEJvhnuk

0

2

0

0

0

Foundation Fighting Blindness

@FightBlindness

about 7 years ago

Jason Menzo presents FFB mission to hundreds of retinal physicians at Ophthalmology Innovation Summit in Chicago. #oisasrs

FightBlindness's tweet photo. Jason Menzo presents FFB mission to hundreds of retinal physicians at Ophthalmology Innovation Summit in Chicago. #oisasrs https://t.co/Iv0myZsKcn

0

9

2

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

Who stood out at #OISASRS? Let’s ask the co-chairs. https://t.co/NDhh4Cy1ks #ophthalmology

0

2

1

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

What were the key takeaways from the second #OISASRS? Learn more: https://t.co/ridv4bPgev #ophthalmology #investing

OISTWEETS's tweet photo. What were the key takeaways from the second #OISASRS? Learn more: https://t.co/ridv4bPgev #ophthalmology #investing https://t.co/9w8LZVpttg

0

3

1

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

We hope you all enjoyed the 2nd Annual #OISASRS. Next stop…New Orleans for OIS@AAO! Cheers!

OISTWEETS's tweet photo. We hope you all enjoyed the 2nd Annual #OISASRS. Next stop…New Orleans for OIS@AAO! Cheers! https://t.co/YXKFiktYbk

0

1

0

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

Thank you @OCUTX for for joining us at our 2nd annual #OISASRS

OISTWEETS's tweet photo. Thank you @OCUTX for for joining us at our 2nd annual #OISASRS https://t.co/Nr9kSaeQhg

0

1

0

0

0

Retina Specialist @RetSpecMag

about 9 years ago

Interesting @Novartis factoid per Dr Dirk Sauer #OISASRS: #ophthalmology 2nd largest unit at Novartis after #oncology @OISTWEETS @RevOphth

0

0

0

0

0

Retina Today @RetinaToday

about 9 years ago · Boston

Angelo Rago talks about the future of retinal imaging at @ZEISSSurgicalUS, including ultra widefield color imaging. #OISASRS

0

2

2

0

0

Retina Today @RetinaToday

about 9 years ago · Boston

Jason Ehrlich reviews @genentech's current pipeline during the Corporate Retina panel. #OISASRS

RetinaToday's tweet photo. Jason Ehrlich reviews @genentech's current pipeline during the Corporate Retina panel. #OISASRS https://t.co/hfUPekbmpY

0

1

3

0

0

Retina Specialist @RetSpecMag

about 9 years ago

#OISASRS Dr Mohamed Genead reports Ph I/II trial of rAAV2/2-ND4 (GenSight) met safety endpoints; Ph III fully enrolled @OISTWEETS @RevOphth

0

4

2

0

0

Katie Ellias @katieellias

about 9 years ago

@GenSightBio Paris company shout out at #OISASRS #hopital1520 @BernardGilly

katieellias's tweet photo. @GenSightBio Paris company shout out at #OISASRS #hopital1520 @BernardGilly https://t.co/uuLH0h2Ojq

0

1

0

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

"The biggest indicator of success is a well-rounded sense of humility." -Angela Macfarlane, President & CEO - ForSight Labs #OISASRS

OISTWEETS's tweet photo. "The biggest indicator of success is a well-rounded sense of humility." -Angela Macfarlane, President & CEO - ForSight Labs #OISASRS https://t.co/kZ7ZSikC6Q

0

1

1

0

0

Katie Ellias @katieellias

about 9 years ago

Interesting discussion on different technologies to address the need for longer duration for AMD, combo therapy vs. reservoirs #OISASRS

0

1

0

0

0

Ophthalmology Innovation Source @OISTWEETS

about 9 years ago

Next up at #OISASRS is the Gene and Cell Therapy session! We're excited to hear the latest!

0

2

1

0

0

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users